• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:20:07 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)

     

    STEREOTAXIS, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    85916J409

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d-1(b)
         
      [X] Rule 13d-1(c)
         
      [  ] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No.  85916J40913GPage 2 of 8 Pages

     

         NAMES OF REPORTING PERSONS
         Opaleye Management Inc.
       
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

       20-5648796

       
         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Massachusetts

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    3,021,436
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    3,021,436

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    3,021,436
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    4.10% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    CO

     

    * Based upon 73,685,629 shares of common stock issued and outstanding on October 31, 2020 as reported by the Issuer on its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

     
    CUSIP No.  85916J40913GPage 3 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       Opaleye, L.P.

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a) [  ]
    2    (b) [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    Delaware

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    3,021,436
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    3,021,436

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    3,021,436
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    4.10% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    PN

     

    * Based upon 73,685,629 shares of common stock issued and outstanding on October 31, 2020 as reported by the Issuer on its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

     
    CUSIP No.  85916J40913GPage 4 of 8 Pages

     

         NAMES OF REPORTING PERSONS
    1

       I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

       James Silverman

         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
         (a)   [  ]
    2    (b)   [  ]
         SEC USE ONLY
       
    3  
         CITIZENSHIP OR PLACE OF ORGANIZATION
       
    4    United States

    NUMBER OF SHARES
    BENEFICIALLY OWNED
    BY EACH REPORTING
    PERSON WITH:
         SOLE VOTING POWER
       
    5    0
         SHARED VOTING POWER
       
    6    3,021,436
         SOLE DISPOSITIVE POWER
       
    7    0
         SHARED DISPOSITIVE POWER
       
    8    3,021,436

         AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    9    3,021,436
         CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    10    [  ]
         PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    11    4.10% *
         TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    12    IN

     

    * Based upon 73,685,629 shares of common stock issued and outstanding on October 31, 2020 as reported by the Issuer on its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

     
    CUSIP No.  85916J40913GPage 5 of 8 Pages

     

    Item 1(a). Name of Issuer:
       
      The name of the issuer is Stereotaxis, Inc. (the “Company”).
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      The Company’s principal executive offices are located at 4320 Forest Park Avenue, Suite 100, St. Louis, Missouri 63108.
       
    Item 2(a). Name of Person Filing.
       
      This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock of the Company:
       
      Opaleye Fund
       
      Opaleye, L.P. (the “Opaleye Fund”), a private fund formed in the state of Delaware.
       
      Investment Manager
       
     

    Opaleye Management Inc. (the “Investment Manager”), with respect to the common shares held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager. The Investment Manager also serves as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. The Investment Manager disclaims beneficial ownership of the shares held by the Managed Account.

       
      Reporting Individual
       
      Mr. James Silverman (the “Reporting Individual”), with respect to the shares of common stock held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.
       
    Item 2(b). Address of Principal Business Office or, if None, Residence.
       
      One Boston Place, 26th Floor
      Boston, Massachusetts 02108
       
    Item 2(c). Citizenship.
       
      Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
       
    Item 2(d). Title of Class of Securities.
       
      Common Stock, $0.001 par value per share
       
    Item 2(e). CUSIP Number.
       
      85916J409

     

     
    CUSIP No.  85916J40913GPage 6 of 8 Pages

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a) [  ] Broker or dealer registered under Section 15 of the Exchange Act.
         
    (b) [  ] Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) [  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
    (d) [  ] Investment company registered under Section 8 of the Investment Company Act.
         
    (e) [  ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) [  ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); 
         
    (g) [  ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) [  ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i) [  ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
         
    (j) [  ] A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) [  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
       
      Opaleye Management Inc. — 3,021,436 shares of common stock*
      Opaleye, L.P. — 3,021,436 shares of common stock*
      James Silverman —3,021,436 shares of common stock*

     

    * Includes 61,436 common shares held by the Managed Account

     

    (b)Percent of class:
      
     Opaleye Management Inc. — 4.10%**
     Opaleye, L.P. — 4.10%**
     James Silverman — 4.10%**

     

    ** Based upon 73,685,629 shares of common stock issued and outstanding on October 31, 2020 as reported by the Issuer on its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2020. This calculation does not include the exercise or conversion of outstanding securities of the Issuer.

     

     
    CUSIP No.  85916J40913GPage 7 of 8 Pages

     

    (c)Number of shares as to which the person has:
        
     (i) Sole power to vote or to direct the vote:
        
       Opaleye Management Inc. — 0 shares
       Opaleye, L.P. — 0 shares
       James Silverman — 0 shares

     

     (ii) Shared power to vote or to direct the vote:
        
       Opaleye Management Inc. — 3,021,436 shares of common stock
       Opaleye, L.P. — 3,021,436 shares of common stock
       James Silverman — 3,021,436 shares of common stock

     

    * Includes 61,436 common shares held by the Managed Account

     

     (iii) Sole power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 0 shares
       Opaleye, L.P. — 0 shares
       James Silverman — 0 shares

     

     (iv) Shared power to dispose or to direct the disposition of:
        
       Opaleye Management Inc. — 3,021,436 shares of common stock
       Opaleye, L.P. — 3,021,436 shares of common stock
       James Silverman —3,021,436 shares of common stock
        
     

    * Includes 61,436 common shares held by the Managed Account

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No.  85916J40913GPage 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 12, 2021 By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.  
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name: James Silverman
      Title: Managing Member of Opaleye
        GP LLC, the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.  
         
    Date: February 12, 2021 By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

     
     

     

    JOINT FILING AGREEMENT

     

    This Joint Filing Agreement, dated February 12, 2021, is entered into by and among Opaleye Management Inc., a Massachusetts corporation, Opaleye, L.P., a Delaware limited partnership and James Silverman, an individual (collectively referred to herein as (the “Filers”). Each of the Filers may be required to file with the U.S. Securities and Exchange Commission a statement on Schedule 13G with respect to shares of common stock, $0.001 par value per share, of Stereotaxis, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    DATED: February 12, 2021

     

      By: /s/ James Silverman
        James Silverman
         
      Opaleye, L.P.
         
      By: /s/ James Silverman
      Name: James Silverman
      Title: Managing Member of Opaleye
        GP LLC, the General Partner of Opaleye, L.P.
         
      Opaleye Management Inc.
         
      By: /s/ James Silverman
      Name: James Silverman
      Title: President

     

       

    Get the next $STXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    SEC Filings

    View All

    SEC Form 424B5 filed by Stereotaxis Inc.

    424B5 - Stereotaxis, Inc. (0001289340) (Filer)

    8/29/25 5:26:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Stereotaxis, Inc. (0001289340) (Filer)

    8/29/25 5:00:59 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Stereotaxis Inc.

    10-Q - Stereotaxis, Inc. (0001289340) (Filer)

    8/13/25 3:00:57 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Stereotaxis with a new price target

    ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

    1/10/24 8:16:33 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aegis Capital initiated coverage on Stereotaxis with a new price target

    Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

    7/12/22 9:20:32 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Stereotaxis with a new price target

    B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

    6/23/22 8:13:15 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/11/25 3:38:02 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/10/25 10:32:20 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    8/20/24 8:38:24 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shamir Nachum was granted 43,668 shares, increasing direct ownership by 96% to 89,276 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:24 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Benfer David was granted 43,668 shares, increasing direct ownership by 10% to 468,924 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:27 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Levin Ross B was granted 43,668 shares, increasing direct ownership by 9% to 531,197 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

    ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world's first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey. "We're excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients," said Dr. Corbisiero, Chief of Electrophysiology at

    9/2/25 8:08:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Present at Upcoming Investor Conferences

    ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. H.C. Wainwright 27th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Lake Street Capital 9th Annual Best Ideas Growth ConferenceMr. Fischel will be available for one-on-one meetings on Thursday, September 11, 2025.

    9/2/25 7:51:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Leadership Updates

    Live Leadership Updates

    View All

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

    ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

    10/21/24 8:41:13 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

    ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

    7/18/24 4:13:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Financials

    Live finance-specific insights

    View All

    Stereotaxis Reports 2025 Second Quarter Financial Results

    ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a

    8/7/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

    ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2025 financial results conference call  When:Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (Interna

    7/23/25 8:00:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Reports 2025 First Quarter Financial Results

    ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

    5/12/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/24 4:26:22 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/23 4:32:50 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/22 5:07:16 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care